BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B

Redeye – focus on commercializing disease modifying treatments

Stockholm, March 7, 2023

Anna-Kaija Grönblad, Chief Operating Officer (COO)

BIOARCTIC

Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- Investigational uses of an agent in development included in this presentation are not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BIOARCTIC

BioArctic – a unique Swedish biopharma company
Improving life for patients with central nervous system disorders



High unmet need

World-class research and development driven organization

Attractive project portfolio

Well-financed

BIOARCTIC

Great partnership with Eisai on lecanemab – preparing for co-promotion in the Nordics

Alzheimer's disease

Partner track record

Eisai

Discovered and developed world's best-selling medicine for symptoms in Alzheimer's

Industry-leading pipeline in dementia area

Aricept donepezil HCl tablet

Used to treat confusion (dementia) related to Alzheimer's disease

Collaboration and license

Milestones of up to

MEUR 136*

remains to be received

Royalties High single digit %

BioArctic retains rights to lecanemab in other indications and option to market in the Nordics

BioArctic has right to commercialize lecanemab in the Nordic under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai.

***) including MEUR 35 to be paid to BioArctic in Q1 2023, based on regulatory approval and submissions**

BIOARCTIC

Recent highlights relating to our lead drug candidate

- In the **U.S.**, lecanemab (brand name: LEQEMBI™) was granted accelerated approval as a treatment for Alzheimer's disease by the FDA on January 6, 2023. Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for a full approval under the traditional pathway on the same day. Priority review granted with PDUFA date July 6, 2023
- In **Europe**, Eisai submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023. The application was accepted for a standard review on January 26
- In **Japan**, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. The application was granted priority review on January 30
- In **China**, Eisai initiated the Biologics License Application (BLA) for lecanemab in December 2022 and it was designated for priority review by the National Medical Products Administration (NMPA) on February 28, 2023

BIOARCTIC

The next step on a transformational journey for BioArctic

- Establish commercial organization in the Nordic countries, incl. support functions and IT infrastructure

- Increase awareness and education in healthcare about;
  - early Alzheimer's disease,
  - current and future diagnostics incl blood-based biomarkers,
  - the possibility of future paradigm-shifting disease modifying treatments
- Prepare patient centric infrastructure to support introduction based on the patient journey



Patient journey for Alzheimer patients will change as treatment options change: will require more resources & new ways of working

Today

In the future



BIOARCTIC

The next step on a transformational journey for BioArctic

- Establish commercial organization in the Nordic countries, incl. support functions and IT infrastructure

- Increase awareness and education in healthcare about;
  - early Alzheimer's disease,
  - current and future diagnostics incl blood-based biomarkers,
  - the possibility of future paradigm-shifting disease modifying treatments
- Prepare patient centric infrastructure to support introduction based on the patient journey

- Support Eisai in preparing pricing and market access applications to demonstrate value of potential products
- Build a solid case for the positioning of lecanemab
- Prepare for Life Cycle Management (subcutaneous formulation, indication expansions)



BIOARCTIC

BioArctic: With Patients in Mind

Great science

Great projects

Great partners

Great people

BIOARCTIC